Izokibep for Uveitis
Trial Summary
What is the purpose of this trial?
This trial tests izokibep, a small protein, in patients with severe eye inflammation who need high-dose steroids. By blocking certain molecules, izokibep aims to reduce inflammation and potentially lower the need for steroids.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it requires that you continue taking stable doses of oral corticosteroids for at least 2 weeks before starting the study.
What data supports the effectiveness of the drug Izokibep for treating uveitis?
How is the drug Izokibep different from other treatments for uveitis?
Izokibep is unique because it may offer a novel approach to treating uveitis by targeting specific immune pathways, potentially providing an alternative to traditional immunosuppressive drugs like corticosteroids and biological agents such as infliximab and adalimumab, which are commonly used in Japan.36789
Research Team
Donald Betah
Principal Investigator
ACELYRIN Inc.
Eligibility Criteria
Adults aged 18-75 with non-infectious intermediate, posterior, or pan-uveitis needing high-dose steroids can join. They must have active disease despite current steroid treatment and give informed consent. Excluded are those with certain eye conditions like serpiginous choroidopathy, high intraocular pressure, very poor vision in one eye, wet macular degeneration, isolated anterior uveitis, suspected infectious uveitis or other specific eye issues.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either izokibep or placebo subcutaneously once weekly
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Izokibep
Find a Clinic Near You
Who Is Running the Clinical Trial?
ACELYRIN Inc.
Lead Sponsor